Nosa Plugs AB (“NOSA” or the “Company”) has carried out a directed share issue at a subscription price of SEK 0.70 per share (the “Directed Issue”) to a select group of family offices and institutional investors, including Eiffel Investment Group (“Eiffel”), through which the Company raises approximately SEK 35 million before deduction of transaction costs.

NOSA’s full press release can be found here.

Background and Rationale
NOSA carried out a directed share issue led by Corpura to finance the strategic acquisition of Pharmacure Health Care International AB (“Pharmacure”) and its main product Nozoil – a world-leading company in lubricating nasal sprays based on natural sesame oil. The acquisition is a clear step in NOSA’s previously communicated growth strategy and is expected to create significant value for shareholders through strong commercial and operational synergies.

In recent years, NOSA has established a leading position within intranasal breathing products, with a proprietary and patented technology platform for controlled substance release. The Company has launched several products with clear demand in areas such as odor removal, microbial protection, and olfactory training, and has recently initiated an ambitious push into drug delivery via the nose – “NOSA Drug Delivery” – an area with high innovation and strong commercial potential.

The acquisition of Pharmacure further strengthens NOSA’s presence in the fast-growing OTC segment and contributes to an increased share of recurring revenues from an already established and profitable business with broad consumer acceptance. At the same time, Pharmacure complements NOSA’s existing product portfolio well.

In connection with the acquisition and the directed issue, the Company also announced new financial targets.

New Financial Targets:

Short-term targets – 2025-2026:

• Growth target – Net revenue of at least SEK 50 million in 2026.
• Profitability target – EBITDA margin of at least 15 percent in 2026.

Medium-term targets – 2027-2028:

• Growth target – Average net revenue growth of at least 25 percent per year.
• Profitability target – EBITDA margin of at least 18 percent.
• Capital structure – Net debt in relation to EBITDA shall not exceed 3x.
• Dividend policy – Surplus shall be distributed to shareholders when free cash flow exceeds available investments in profitable growth. Dividend to shareholders assumes the capital structure target is met.

CEO Adrian Liljefors comments:
“There has been an overwhelming interest in participating in the directed issue, and I am very pleased to welcome, among others, Eiffel Investment Group as a new institutional shareholder in NOSA. Their decision to invest is the result of a thorough and extensive due diligence process. Their experience, long-term perspective, and commitment make them a valuable partner on our continued expansive journey. We are convinced that this partnership will help accelerate our growth and create further long-term value for all our shareholders.

I would also like to extend a big thank you to the existing shareholders who continue to support NOSA on our journey to become ‘Leaders within nasal health and beyond’.”

About Nosa Plugs AB
Nosa Plugs AB (publ) is a Swedish medical technology company listed on Nasdaq First North Growth Market since March 16, 2023, under the ticker "NOSA". FNCA Sweden AB is Certified Adviser.

NOSA’s press releases are available at: https://nosaplugs.com/sv/investerare/

Corpura Fondkommission acted as Sole Coordinator and Bookrunner in connection with the Directed Issue.

For more information contact:
Christopher Sebök
Phone: +46(0)72-995 43 97
Email: christopher.sebok@corpura.se